



Mark Lewandowski, Commission Chair Melanie Maxwell, Commission Co-Chair Vacant, Commission Member

Rose Thomas-Bendel, Commission Member Anthony J. "A.J." Ferate, Commission Member Gena Perry, Commission Member Teah Corley, Commission Member

PIN: 65715

## SPECIAL MEETING OF THE PATIENT'S RIGHT TO PHARMACY CHOICE COMMISSION

Thursday, July 27, 2023 at 1:30 p.m.

Oklahoma Insurance Department 400 NE 50th Street Oklahoma City, OK 73120

A teleconference line will be available for the public to utilize during the business portion of the meeting. A teleconference line will not be available during any hearings scheduled before the Commission.

CONFERENCE LINE: +1-866-846-9071 United States (Toll Free)

## **AGENDA**

- I. Call to Order
- II. Roll Call, Recognition of Quorum, Statement of Compliance with OMA
- III. Discussion and Possible Action to Approve Minutes from June 15, 2023, Meeting
- Presentation and Discussion of 2023- 2<sup>nd</sup> Quarterly Report to Pharmacy Choice IV. Commission – Ashley Scott, Director of PBM Compliance and Enforcement
- V. Hearings-Chariman Mark Lewandowski

## Hearings before the Commission:

The hearings before the Commission will be conducted pursuant to the authority and jurisdiction of the Oklahoma Insurance Code, Title 36 O.S. §§ 101 et seq., Title 36 O.S. §§ 307, Title 59 O.S. § 356-360, and the Patient's Right to Pharmacy Choice Act, Title 36 O.S. §§ 6958-6968, the Oklahoma Insurance Department's Permanent Rules, OAC Title 365, and the Administrative Procedures Act Title 75 O.S. §§ 250 et seq.

THE FOLLOWING MATTERS ARE PRESENTED FOR CONSIDERATION AND ACTION, IF ANY, DEEMED APPROPRIATE BY THE COMMISSION.



Insurance Commissioner, Glen Mulready

Mark Lewandowski, Commission Chair Melanie Maxwell, Commission Co-Chair Vacant, Commission Member

Rose Thomas-Bendel, Commission Member Anthony J. "A.J." Ferate, Commission Member Gena Perry, Commission Member Teah Corley, Commission Member

- 1) Presentation, Discussion and Possible Action on Motion for Continuance on Case No. 22-0443-DIS, State of Oklahoma v. Prime Therapeutics, L.L.C.:
  - b) Opposed Motion of Continuance;
  - c) Possible executive session for the purpose of deliberating and/or rendering a final or intermediate decision on any issues or motions raised in this proceeding pursuant to Title 25 O.S. § 307(B)(8).

**Possible Action:** Possible action may include, but is not limited to: taking no action; continuing the matter; issuing an order; or taking preliminary action in the matter. The Commission may instruct State or Respondent Counsel or staff to draft a proposed order to be considered in further deliberations and at a future Commission meeting.

## VI. Adjourn

Note: The Commission may, at its discretion, discuss, vote to approve, vote to disapprove, vote to table, change the sequence of any agenda item, vote to strike or not discuss any agenda item.